In close timing with the FDA’s approval of edoxaban for reducing the risk of stroke in patients with atrial fibrillation, researchers reported that an agent reversed edoxaban’s anticoagulant effect in a phase 1 study.

The FDA followed the advice of its advisory panel and added another novel oral anticoagulant to its approved drug list.

The Department of Justice (DoJ) is taking the reins in two lawsuits filed against a Florida cardiologist who made headlines in 2014 for billing Medicare $18 million in one year. The DoJ alleges he performed medically unnecessary interventions and paid kickbacks to patients.

The FDA approved Medtronic’s drug-coated balloon as a treatment for peripheral artery disease (PAD), giving physicians more options for treating patients with disease in the superficial femoral artery and the popliteal artery.

A meta-analysis of blood pressure monitoring studies supports closely monitoring patients at risk for hypertension and cardiovascular disease. This included support for using ambulatory methods on patients in order to prevent overdiagnosis due to office-related elevated blood pressure.

Hoping to reduce the frequency of unnecessary imaging in older patients, research published in the December issue of CHEST explored a sliding adjustment scale to D-dimer testing for pulmonary embolism.

A talent void is pending among stroke specialists, according to a study published in the December issue of Stroke. The question posed by the authors is how to increase the number of young vascular neurologists entering the pipeline to compensate for losses.

The removing ability of high-density lipoprotein (HDL) cholesterol may be the secret behind apparently “good” cholesterol, according to a study published Dec. 18 in the New England Journal of Medicine.